FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC

NCT07729605 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

270

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic
Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Interventions

DRUG: FOLFIRI + bevacizumab + QL1706
DRUG: FOLFIRI + bevacizumab

Sponsor

Sun Yat-sen University